NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
Skip to content
OVERVIEW
Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
Decipher Prostate test specifically cited for its extensive clinical evidence, including from multiple phase 3 randomized trials in high-risk prostate cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that an updated clinical
View HTML
Toggle Summary Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
Findings to Focus on Ability of Immunoscore IC Test to Predict Efficacy of Immune Checkpoint Inhibitors in Patients with NSCLC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that six abstracts demonstrating the ability of its genomic and
View HTML

Events

There are currently no events to display.

Presentations

Title Documents

Corporate Presentation March 2022